{
    "name": "thiotepa",
    "comment": "Rx",
    "other_names": [
        "tespa",
        "Thioplex",
        "Triethylenethiophosphoramide",
        "TSPA"
    ],
    "classes": [
        "Antineoplastics",
        "Alkylating"
    ],
    "source": "https://reference.medscape.com/drug/tespa-thioplex-thiotepa-342111",
    "pregnancy": {
        "common": [
            "Pregnancy Category: D",
            "Lactation: not known if excreted in breast milk, do not nurse"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: not known if excreted in breast milk, do not nurse"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Hepatic, renal, bone marrow damage (maybe used in low dose if benefit>risk)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Avoid pregnancy",
                "May be mutagenic and teratogenic",
                "Myelosuppression may occur",
                "Secondary malignancies may develop (potentially carcinogenic)",
                "Caution in hepatic impairment (may require dose reduction; use may also be contraindicated depending on type of hepatic impairment)",
                "Caution in renal impairment (may require dose reduction; use may also be contraindicated depending on type of hepatic impairment)",
                "Use appropriate precautions for handling and disposal"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "adenovirus types 4 and 7 live, oral",
            "description": {
                "common": "thiotepa decreases effects of adenovirus types 4 and 7 live, oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressives may diminish therapeutic effects of vaccines and increase risk of adverse effects (increased risk of infection). Live-attenuated vaccines should be avoided for at least 3mo after cessation of immunosuppressive therapy."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axicabtagene ciloleucel",
            "description": {
                "common": "thiotepa, axicabtagene ciloleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brexucabtagene autoleucel",
            "description": {
                "common": "thiotepa, brexucabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ciltacabtagene autoleucel",
            "description": {
                "common": "thiotepa, ciltacabtagene autoleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "deferiprone",
            "description": {
                "common": "deferiprone, thiotepa.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis; if an alternative is not possible, monitor absolute neutrophil count more frequently."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idecabtagene vicleucel",
            "description": {
                "common": "thiotepa, idecabtagene vicleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine quadrivalent, adjuvanted",
            "description": {
                "common": "thiotepa decreases effects of influenza virus vaccine quadrivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "influenza virus vaccine trivalent, adjuvanted",
            "description": {
                "common": "thiotepa decreases effects of influenza virus vaccine trivalent, adjuvanted by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Immunosuppressive drugs may reduce the immune response to influenza vaccine."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisocabtagene maraleucel",
            "description": {
                "common": "thiotepa, lisocabtagene maraleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palifermin",
            "description": {
                "common": "palifermin increases toxicity of thiotepa by Other (see comment). Avoid or Use Alternate Drug. \nComment: Palifermin should not be administered within 24 hrbefore, during infusion of, or within 24 hr after administration of antineoplastic agents. Coadministration of palifermin within 24 hr of chemotherapy resulted in increased severity and duration of oral mucositis."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ropeginterferon alfa 2b",
            "description": {
                "common": "ropeginterferon alfa 2b, thiotepa.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Myelosuppressive agents can produce additive myelosuppression. Avoid use and monitor patients receiving the combination for effects of excessive myelosuppression."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tisagenlecleucel",
            "description": {
                "common": "thiotepa, tisagenlecleucel.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "thiotepa, tofacitinib.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belatacept",
            "description": {
                "common": "belatacept and thiotepa both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bendamustine",
            "description": {
                "common": "bendamustine, thiotepa.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "busulfan",
            "description": {
                "common": "busulfan, thiotepa.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carmustine",
            "description": {
                "common": "carmustine, thiotepa.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorambucil",
            "description": {
                "common": "chlorambucil, thiotepa.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholera vaccine",
            "description": {
                "common": "thiotepa decreases effects of cholera vaccine by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Immunosuppressive therapies, including irradiation, antimetabolites, alkylating agents, cytotoxic drugs and corticosteroids (used in greater than physiologic doses), may reduce the immune response to cholera vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cisplatin",
            "description": {
                "common": "cisplatin, thiotepa.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide, thiotepa.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dacarbazine",
            "description": {
                "common": "dacarbazine, thiotepa.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dengue vaccine",
            "description": {
                "common": "thiotepa decreases effects of dengue vaccine by immunosuppressive effects; risk of infection. Use Caution/Monitor. Immunosuppressive therapies (eg, irradiation, antimetabolites, alkylating agents, cytotoxic drugs, corticosteroids [greater than physiologic doses]) may reduce immune response to dengue vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "denosumab",
            "description": {
                "common": "thiotepa, denosumab. Other (see comment). Use Caution/Monitor. \nComment: Caution should be taken in patients on concomitant immunosuppressants or with impaired immune systems because of increased risk for serious infections."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eluxadoline",
            "description": {
                "common": "thiotepa increases levels of eluxadoline by affecting hepatic enzyme CYP2B6 metabolism. Use Caution/Monitor. As a precautionary measure due to incomplete information on the metabolism of eluxadoline, use caution when coadministered with strong CYP2B6 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "thiotepa increases effects of fingolimod by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely. Concomitant therapy is expected to increase the risk of immunosuppression. Use caution when switching patients from long-acting therapies with immune effects. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyurea",
            "description": {
                "common": "thiotepa, hydroxyurea. Other (see comment). Use Caution/Monitor. \nComment: Avoid combination. Combination may increase risk of myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "ifosfamide, thiotepa.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "incobotulinumtoxinA",
            "description": {
                "common": "thiotepa increases levels of incobotulinumtoxinA by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza A (H5N1) vaccine",
            "description": {
                "common": "thiotepa decreases effects of influenza A (H5N1) vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce immune response to H5N1 vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "influenza virus vaccine (H5N1), adjuvanted",
            "description": {
                "common": "thiotepa decreases effects of influenza virus vaccine (H5N1), adjuvanted by pharmacodynamic antagonism. Use Caution/Monitor. Immunosuppressive therapies may reduce immune response to H5N1 vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "thiotepa and isavuconazonium sulfate both decrease  immunosuppressive effects; risk of infection. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomustine",
            "description": {
                "common": "lomustine, thiotepa.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration with lomustine may increase the risk of immunosuppression and myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mechlorethamine",
            "description": {
                "common": "mechlorethamine, thiotepa. pharmacodynamic synergism. Use Caution/Monitor. Coadministration with mechlorethamine may increase the risk of immunosuppression and myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meningococcal group B vaccine",
            "description": {
                "common": "thiotepa decreases effects of meningococcal group B vaccine by pharmacodynamic antagonism. Use Caution/Monitor. Individuals with altered immunocompetence may have reduced immune responses to the vaccine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofatumumab SC",
            "description": {
                "common": "ofatumumab SC, thiotepa.\nEither increases effects of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Consider the risk of additive immune system effects when coadministering immunosuppressive therapies with coadministration. When switching from therapies with immune effects, take into account the duration and mechanism of action of these therapies when initiating ofatumumab SC."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olaparib",
            "description": {
                "common": "thiotepa and olaparib both increase  pharmacodynamic synergism. Use Caution/Monitor. Coadministration with other other myelosuppressive anticancer agents, including DNA damaging agents,  may potentiate and prolongate the myelosuppressive toxicity. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod and thiotepa both increase  immunosuppressive effects; risk of infection. Use Caution/Monitor. Caution if coadministered because of additive immunosuppressive effects during such therapy and in the weeks following administration. When switching from drugs with prolonged immune effects, consider the half-life and mode of action of these drugs to avoid unintended additive immunosuppressive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sipuleucel-T",
            "description": {
                "common": "thiotepa decreases effects of sipuleucel-T by pharmacodynamic antagonism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "streptozocin",
            "description": {
                "common": "streptozocin, thiotepa.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Additive myelosuppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab",
            "description": {
                "common": "trastuzumab, thiotepa.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trastuzumab deruxtecan",
            "description": {
                "common": "trastuzumab deruxtecan, thiotepa.\nEither increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor.  Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zidovudine",
            "description": {
                "common": "thiotepa, zidovudine.\nEither increases toxicity of the other by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of myelosuppression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin A",
            "description": {
                "common": "vitamin A, thiotepa. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin A enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vitamin E",
            "description": {
                "common": "vitamin E, thiotepa. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Antioxidants such as vitamin E enhance the efficacy, and reduce toxicity, of antineoplastic drugs."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Seizures",
            "percent": null
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Vomiting",
            "percent": null
        },
        {
            "name": "Loss of appetite",
            "percent": null
        },
        {
            "name": "Stomatitis",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Myelosuppression",
            "percent": null
        },
        {
            "name": "Leukemia",
            "percent": null
        },
        {
            "name": "Immune hypersensitivity reaction",
            "percent": null
        },
        {
            "name": "Oligozoospermia",
            "percent": null
        },
        {
            "name": "Amenorrhea",
            "percent": null
        },
        {
            "name": "Alopecia",
            "percent": null
        },
        {
            "name": "slow",
            "percent": null
        },
        {
            "name": "Hyperpigmentation",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Injection site pain",
            "percent": null
        }
    ]
}